Compare Lam Research Corporation (LRCX) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lam Research Corporation vs Koninklijke Philips NV — how do they compare? Lam Research Corporation trades at $318.84 (market cap $401.19B), while Koninklijke Philips NV trades at $24.24 (market cap $23.52B). The key difference: Lam Research Corporation is far larger — about 17.1× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (4.17%). Which is the better fit depends on your goals — on Pluang, investors hold Lam Research Corporation for 60 Days and Koninklijke Philips NV for 84 Days on average.
| LRCX | PHG | |
|---|---|---|
Market Cap | $401.19B | $23.52B |
Volume | 8,960,892 | 1,635,069 |
Sector | Technology | Health |
52-Week High | $433.33 | $32.91 |
52-Week Low | $131.37 | $23.81 |
Typical Hold Time | 60 Days | 84 Days |
Enterprise Value | $399.35B | $29.87B |
Dividend Yield | 0.41% | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $320.59, down 2.71% on the day, amid a bearish technical signal despite strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.82 surpassing the $1.69 estimate, and maintains high profitability with a net income margin of 31.27%. Revenue growth is accelerating, reaching $18.44 billion in 2025, supported by AI-driven demand for semiconductor equipment. Analyst consensus remains strongly bullish with a $375.68 price target, though technical indicators show mixed signals with key support at $314.
LRCX presents a compelling long-term investment opportunity driven by AI infrastructure spending and operational efficiency, but faces near-term volatility from technical bearishness and macroeconomic headwinds. Risks include cyclical semiconductor demand and competitive pressures, yet strong institutional support and consistent earnings outperformance underpin upside potential toward analyst targets.
PHG trades at $24.30, up 0.87% with a bearish technical signal despite three consecutive quarterly earnings beats. The company shows improving fundamentals with net income turning positive at $895 million in 2025 after previous losses, supported by strong operational cash flow of $1.17 billion. Recent developments include new product launches in healthcare technology and a $33.7 million ARPA-H award for AI-enabled stroke care.
While analyst consensus leans Hold (63.64%), the improving profitability trajectory and reasonable valuation (P/E 18.94) present opportunity, though technical weakness and competitive healthcare market risks require monitoring. The stock faces resistance near $25 with support at $24, with institutional ownership showing mixed signals through recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
